DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF

1 .- 38 . (canceled)

39 . A binding protein comprising first and second polypeptide chains, each independently comprising VD1-(X1)n-VD2-C—(X2)n, wherein

VD1 is a first variable domain;

VD2 is a second variable domain;

C is a constant domain;

X1 is a linker;

X2 is an Fc region;

n is 0 or 1,

wherein the VD1 domains on the first and second polypeptide chains form a first functional target binding site and the VD2 domains on the first and second polypeptide chains form a second functional target binding site, and wherein the binding protein is capable of binding EGFR and EGFR, wherein the variable domains that form functional target binding sites for EGFR independently comprise

CDRs 1-3 from SEQ ID NO: 49 and CDRs 1-3 from SEQ ID NO: 50, or

CDRs 1-3 from SEQ ID NO: 39 and CDRs 1-3 from SEQ ID NO: 40.

40 . The binding protein of claim 39 , wherein the binding protein is capable of binding EGFR and EGFR, wherein the variable domains that form functional target binding sites for EGFR independently comprise

SEQ ID NO: 49 and SEQ ID NO: 50, or

SEQ ID NO: 39 and SEQ ID NO: 40.

41 . The binding protein of claim 39 , comprising first and second polypeptide chains, wherein

the first polypeptide chain comprises a first VD1-(X1)n-VD2-C—(X2)n, wherein

VD1 is a first heavy chain variable domain;

VD2 is a second heavy chain variable domain;

C is a heavy chain constant domain;

X1 is a linker;

X2 is an Fc region;

n is 0 or 1; and

the second polypeptide chain comprises a second VD1-(X1)n-VD2-C—(X2)n, wherein

VD1 is a first light chain variable domain;

VD2 is a second light chain variable domain;

C is a light chain constant domain;

X1 is a linker;

n is 0 or 1 for (X1)n; and

n is 0 for (X2)n.

42 . The binding protein of claim 39 , wherein X1 is not CH1 or CL.

43 . The binding protein of claim 39 , wherein X1 is selected from the group consisting of SEQ ID NOs: 1-26, a G/S sequence, and SEQ ID NO: 329.

44 . The binding protein of claim 39 , wherein the Fc region is a native sequence Fc region or a variant sequence Fc region.

45 . The binding protein of claim 39 , wherein the Fc region is from an IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, or IgD.

46 . The binding protein of claim 39 , wherein the binding protein is capable of binding EGFR and EGFR and comprises

DVD321 (comprising SEQ ID NO: 59 and SEQ ID NO: 60),

DVD322 (comprising SEQ ID NO: 61 and SEQ ID NO: 62),

DVD765 (comprising SEQ ID NO: 63 and SEQ ID NO: 64),

DVD766 (comprising SEQ ID NO: 65 and SEQ ID NO: 66),

DVD795 (comprising SEQ ID NO: 67 and SEQ ID NO: 68),

DVD796 (comprising SEQ ID NO: 69 and SEQ ID NO: 70),

DVD825 (comprising SEQ ID NO: 71 and SEQ ID NO: 72), or

DVD826 (comprising SEQ ID NO: 73 and SEQ ID NO: 74).

47 . The binding protein of claim 39 , wherein the binding protein is capable of binding EGFR and EGFR and comprises

SEQ ID NO: 59 and SEQ ID NO: 60,

SEQ ID NO: 61 and SEQ ID NO: 62,

SEQ ID NO: 63 and SEQ ID NO: 64,

SEQ ID NO: 65 and SEQ ID NO: 66,

SEQ ID NO: 67 and SEQ ID NO: 68,

SEQ ID NO: 69 and SEQ ID NO: 70,

SEQ ID NO: 71 and SEQ ID NO: 72, or

SEQ ID NO: 73 and SEQ ID NO: 74.

48 . The binding protein of claim 39 , wherein the binding protein comprises two first polypeptide chains and two second polypeptide chains and four functional target binding sites.

49 . The binding protein of claim 39 , wherein the binding protein is a crystallized binding protein.

50 . A binding protein conjugate comprising the binding protein of claim 39 , the binding protein conjugate further comprising an immunoadhesion molecule, an imaging agent, a therapeutic agent, or a cytotoxic agent.

51 . The binding protein conjugate of claim 50 , wherein the imaging agent is a radiolabel, an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a magnetic label, or biotin.

52 . The binding protein conjugate of claim 51 , wherein the radiolabel is 3 H, 14 C, 35 S, 90 Y, 99 Tc, 111 In, 125 I, 131 I, 177 Lu, 166 Ho, or 153 Sm.

53 . The binding protein conjugate of claim 50 , wherein the therapeutic or cytotoxic agent is an anti-metabolite, an alkylating agent, an antibiotic, a growth factor, a cytokine, an anti-angiogenic agent, an anti-mitotic agent, an anthracycline, a toxin, or an apoptotic agent.

54 . A pharmaceutical composition comprising the binding protein of claim 39 and a pharmaceutically acceptable carrier.

55 . The pharmaceutical composition of claim 54 , further comprising at least one additional therapeutic agent.

56 . The pharmaceutical composition of claim 55 , wherein the additional therapeutic agent is selected from the group consisting of an imaging agent, a cytotoxic agent, an angiogenesis inhibitor, a kinase inhibitor, a co-stimulation molecule blocker, an adhesion molecule blocker, an anti-cytokine antibody or functional fragment thereof, methotrexate, cyclosporin, rapamycin, FK506, a detectable label or reporter, a TNF antagonist, an antirheumatic, a muscle relaxant, a narcotic, a non-steroid anti-inflammatory drug (NSAID), an analgesic, an anesthetic, a sedative, a local anesthetic, a neuromuscular blocker, an antimicrobial, an antipsoriatic, a corticosteroid, an anabolic steroid, an erythropoietin, an immunization, an immunoglobulin, an immunosuppressive, a growth hormone, a hormone replacement drug, a radiopharmaceutical, an antidepressant, an antipsychotic, a stimulant, an asthma medication, a beta agonist, an inhaled steroid, an epinephrine or analog, a cytokine, and a cytokine antagonist.

57 . A kit for assaying a test sample for the presence, amount, or concentration of EGFR, or a fragment thereof, wherein the kit comprises

a. instructions for assaying the test sample for the target or fragment thereof, and

b. at least one binding protein comprising the binding protein of claim 39 .